Santen
Text Size
Listen
Santen Global
  • Patients
  • Healthcare Professionals
  • Careers
  • Investors
Listen

Tap on the left to use.

  • Who We Are
    Message
    Message from the CEO
    Santen’s Corporate Philosophy Framework
    Santen’s Corporate Philosophy Framework
    History
    History of Santen
    Corporate Executives
    Corporate Executives
    Corporate Governance
    Corporate Governance
    Policies
    Policies and Statements
    Company Infomation
    Overview / Map
    Global Operation
  • What We Do
    MTP & Santen 2030
    Medium-term Management Plan
    Santen 2030
    Efforts to Enhance Patients' Satisfaction
    Efforts to Enhance Product Safety
    Efforts to Enhance Product Usability
    Efforts to Address Untreated Patients
    Research & Development
    Research & Development
    The Ophthalmic Development Process
    Clinical Trial Information
    Partnering
    Santen's Partnership
    Our Partners
    Partnering Contact
    Production
    Production
    Safety and Quality Assurance
    The Ophthalmic Production Process
    Sales & Marketing
    Sales & Marketing
  • Our Stories
  • Sustainability
    Sustainability
    Our Sustainability Commitment
    Sustainability at Santen
    Social
    Access to Healthcare
    Research & Development in Ophthalmology
    Product Quality & Safety
    Supply Chain
    Human Rights
    Talent
    Digital Transformation (DX)
    Governance
    Corporate Governance
    Compliance
    Ethical Marketing
    Risk Management
    Information Security
    Environment​
    Environmental initiatives
    Measures against Climate Change
    Environmental Load Reduction
    Biodiversity
    Disclosures Based on the TCFD Recommendations
    Inclusion
    Inclusive Society Santen Promotes
    Inclusion Starting from Blind Football
    Together with Society
    With Employees
    Related Information
    Participating in the UN Global Compact
    Social Contribution Activities
    Stakeholder Engagement
    Environment Data (up-to-date)
    Social Data (up-to-date)
    Governance Data (up-to-date)
    GRI Standards Content Index
    Sustainability Library
    External Assessment
  • News
    News
    Show All
    Press Release
    IR News
    Information
  1. HOME
  2. News
  3. 2013

2013 News

  • Press Release
  • IR News
  • Information

Press Release

12.09.2013 Notice on the Establishment of Subsidiary in Singapore
12.09.2013 Santen Launches Sante ALn, an OTC Eye Drop, and Redesign Packaging for Sante AL Cool II and Sante ALFree New Eye Drop
12.09.2013 Santen Launches Sante PC (Pouch Type), an OTC Eye Drop in Limited Quantities on December 9, 2013
12.06.2013 European marketing authorization application for Ikervis has been filed to the EMA for the treatment of Dry Eye Disease
11.29.2013 Santen to Support People in the Philippines Affected by Typhoon Haiyan through Donations
Press Release

IR News

12.09.2013 Notice on the Establishment of Subsidiary in Singapore
12.06.2013 European marketing authorization application for Ikervis has been filed to the EMA for the treatment of Dry Eye Disease
11.29.2013 Santen to Support People in the Philippines Affected by Typhoon Haiyan through Donations
11.25.2013 Santen Launches Alesion® 0.05% Ophthalmic Solution for Allergic Conjunctivitis Treatment in Japan
11.22.2013 Intravitreal VEGF Inhibitor "EYLEA" Obtains Additional Indication of Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)
IR News

Information

10.09.2013 Santen to release Annual Report 2013
07.29.2013 Santen to launch its New Group Website
06.03.2013 Notice of the Relocation of Head Office
Information
News Archive

Official SNS

LinkedIn YouTube
  • Accessibility
  • Terms of Use
  • Privacy Policy
  • Contact
Copyright © 2023 Santen Pharmaceutical Co., Ltd.
All Rights Reserved